NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Up 5.8% – What’s Next?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) rose 5.8% on Monday. The stock traded as high as $23.74 and last traded at $23.8850. Approximately 708,318 shares were traded during trading, a decline of 37% from the average session volume of 1,118,843 shares. The stock had previously closed at $22.58.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Royal Bank Of Canada lowered their price objective on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group restated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and a consensus price target of $49.73.

NewAmsterdam Pharma Price Performance

The business has a 50 day simple moving average of $26.25 and a 200 day simple moving average of $30.46. The company has a market capitalization of $2.83 billion, a price-to-earnings ratio of -11.03 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $2.83 million. On average, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director John W. Smither sold 1,600 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares of the company’s stock, valued at $221,803.20. This trade represents a 15.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Louise Kooij sold 105,000 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares of the company’s stock, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 231,600 shares of company stock worth $6,589,962. 12.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NAMS. Frazier Life Sciences Management L.P. grew its stake in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after purchasing an additional 1,145,128 shares in the last quarter. Capital World Investors boosted its stake in shares of NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after buying an additional 161,289 shares during the period. Maverick Capital Ltd. grew its position in shares of NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock worth $69,987,000 after buying an additional 292,176 shares in the last quarter. Castle Hook Partners LP acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Finally, First Turn Management LLC increased its stake in shares of NewAmsterdam Pharma by 24.6% during the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company’s stock worth $31,343,000 after buying an additional 176,502 shares during the period. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.